Making weight loss injections available to all eligible individuals in the U.K. could yield an economic boost of 4.5 billion ...

In the first head-to-head trial of its kind, people with obesity who took tirzepatide (sold under the brand names Mounjaro ...

The millions of people living with obesity need novel treatment options that are safe, effective and avoid the high costs and ...

Danish pharmaceutical giant Novo Nordisk is saying goodbye to its chief executive amid growing competition for its ...

While natural approaches to raising GLP-1 are not as potent as medications, they provide a drug-free approach to weight loss ...

Weight loss drugs Ozempic and Wegovy would no longer be covered by California’s health insurance for low-income people under ...

New research has found that GLP-1 drugs can substantially reduce the risk of obesity-related cancers — and they’re more ...

It’s been nearly two years since the FDA approved their use in kids, but some are questioning if these drugs are safe for ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Ozempic was approved to treat Type 2 diabetes in 2017, and it's become increasingly popular among those who don't have the disease.

Costly drugs: The drugs prescribed to fight obesity have been driving up the cost of Medi-Cal, the state program that ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...